Cross-sectional study quantifies serum AGEs in different metabolic states, suggesting their role in complication risk evaluation.
BACKGROUND: Advanced glycation end products (AGEs) link chronic hyperglycaemia to diabetic tissue damage. Serum AGE concentrations across the metabolic disease spectrum, from prediabetes through complicated diabetes, remain incompletely characterized, including the contribution of isolated dyslipidaemia. OBJECTIVE: To quantify serum AGEs across metabolic states and evaluate their biomarker potential for disease staging and complication risk stratification. METHODS: Cross-sectional study of 226 adults in five groups: healthy controls, isolated hyperlipidaemia, impaired glucose tolerance, uncomplicated type 2 diabetes, and complicated type 2 diabetes. Serum AGEs were measured by ELISA. Group differences were assessed by Kruskal-Wallis tests, logistic regression, and receiver operating characteristic analysis. RESULTS: = .016). CONCLUSION: Serum AGEs rise progressively from prediabetes to complicated diabetes, driven by hyperglycaemia. Their discriminative capacity where conventional glycaemic markers plateau supports AGEs as a complementary biomarker for complication risk stratification, pending validation.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: